Results 171 to 180 of about 142,538 (255)

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

BMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen, Weichen Zhang, Gaoli Niu, Li Wang, Ruiyan Li, Yueyue Fan, Feixue Lu, Lingling Xu, Xiaoyuan Ji, Yong Kang   +9 more
wiley   +1 more source

Targeting STAT3 in systemic lupus erythematosus and lupus nephritis: mechanisms, therapeutic advances, and structure-informed perspectives. [PDF]

Front Pharmacol
Yi F, Tu X, Jin R, Zhou J, Li Y, Liao H, Xu W, Yuan Y, Wu M, Bi P, Yin J.   +10 more
europepmc   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović, Ingrid Tomljanović, Wieke H. Grievink, Diana R. Pereira, Michelle Osse, Peter van Balen, Maria J. Juachon, Marieke L. de Kam, Lisa Pagan, Manon A.A. Jansen, Matthijs Moerland, Jacobus J. Bosch   +11 more
wiley   +1 more source

Helicase A determines the transcription program of T_H17 lineage differentiation and autoimmunity. [PDF]

Sci Adv
Su Y, Jiao A, Zhang X, Xu Y, Ping H, Zhu K, Wang Q, Yuan N, Gao Y, Ju B, Ding R, Wang N, He L, Lei L, Zhao Y, Zhang M, Zhang B.   +16 more
europepmc   +1 more source

Biography as the Missing Variable in Drug Development: A Case for Bio‐Biographical Mechanistic Profiling

Clinical Pharmacology &Therapeutics, EarlyView.
Most clinical trial failures reflect unmeasured biological heterogeneity. Biography — chronic stress, adversity, trauma, and social isolation—is a neglected source of that heterogeneity, operating through the same molecular pathways drugs engage.
Ralph I. Horwitz
wiley   +1 more source

Dynamic, anthracycline-induced chromatin alterations enable ALDH1 expression as a mechanism of inducible leukemia resistance development. [PDF]

Blood Res
Vlahopoulos SA.
europepmc   +1 more source

Differential sensitivity to SHH signaling and neural crest‐mediated Gas1 expression regulate jaw size during development and evolution

Developmental Dynamics, EarlyView.
Abstract Background Developmental control of jaw size is crucial to prevent birth defects and facilitate evolutionary adaptation. We have shown that jaw size is established by neural crest mesenchyme (NCM), which are progenitor cells that migrate into the mandibular primordia and produce the jaws.
Zuzana Vavrušová, Daniel B. Chu, An Nguyen, Yeniko Ta, Jennifer L. Fish, Richard A. Schneider   +5 more
wiley   +1 more source

Targeting the JAK/STAT pathway with isoliquiritigenin in ovarian cancer: molecular mechanisms and therapeutic implications. [PDF]

Front Pharmacol
Ding M, Guo F, Lin P.
europepmc   +1 more source

Hepatic Mechanisms and Therapeutic Target Underpinning Hypercoagulation in Obesity: Insights From Genetic and Transcriptomic Analyses

Exploration, EarlyView.
Obesity‐linked hypercoagulation is driven by fibrinogen overproduction in a specific hepatocyte cluster via IL6 signalling. Genetic and mechanistic studies reveal this pathway as a key target for therapies to mitigate clotting risks and associated complications in obese individuals.
Shumin Li, Gengchen Feng, Xin Huang, Xiao Teng, Ziyi Yang, Yue Liu, Yonghui Jiang, Tao Zhu, Teng Liu, Yunfei Xu, Chang Pan, Han Zhao, Shaozhuang Liu, Shigang Zhao, Zi‐Jiang Chen   +14 more
wiley   +1 more source

Network Pharmacology & Validation of Dihydrotanshinone I's Regulation of HIF-1α via STAT3 in Cardiomyocytes. [PDF]

Acta Cardiol Sin
Zhao J, Zhang X, Liu Y, Jiang C, Wang L.
europepmc   +1 more source